: £13.0 million (+52.9%), driven by AMR and EMEAI growth.
: Continued advancement in national programs like NIHR Bioresource. Strategic and Operational Developments
: A refined commercial strategy identified high-priority opportunities in applied and research markets worth an estimated $13 to $14 billion .